{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-25-000037","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.937672+00:00","generated_at":"2026-05-18T17:35:26.306372+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Altimmune's pemvidutide Phase 2b MASH trial hits primary endpoint; 59.1% resolution vs 19.1% placebo (p<0.0001)","bullets":["MASH resolution without worsening fibrosis: 59.1% (1.2mg) and 52.1% (1.8mg) vs 19.1% placebo (p<0.0001).","Fibrosis improvement not significant on primary, but AI analysis showed 30.6% achieving ≥60% reduction (p<0.001).","Weight loss of 5.0% (1.2mg) and 6.2% (1.8mg) vs 1.0% placebo (p<0.001); trajectory not plateauing at 24 weeks.","AE-related discontinuations <1.2% in pemvidutide arms vs 2.4% placebo; no SAEs related to study drug."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-25-000037","json":"https://secwatch.observer/filing/0001326190-25-000037.json","markdown":"https://secwatch.observer/filing/0001326190-25-000037.md","text":"https://secwatch.observer/filing/0001326190-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000037/0001326190-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000037/alt-20250626x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:35:26.306372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}